Oruka Therapeutics, Inc. (ORKA)
$78.19-2.69%Close
SELLCRISIS · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.9B
- Beta
- -0.39
- P/E (TTM)
- -31.66
- Short % float
- 29.38%
- Days to cover
- 6.3
- SI change
- +2.0%
- 1W
- -2.48%
- 1M
- -18.49%
- vs SPY 1W
- -2.34%
- vs SPY 1M
- -21.00%
Industry peers
FMP comparable companies · ranked by market cap
- DNTHSELLDianthus Therapeutics, Inc.$4.6BCRISISQ 2$82.43-4.89%
- XNCRSELLXencor, Inc.$1.8BRECOVERYQ 15$24.50-6.07%
- ANABSELLAnaptysBio, Inc.$1.4BCRISISQ 25$46.21-0.98%
- MLTXSELLMoonLake Immunotherapeutics$890MCRISISQ -1$10.58-2.53%
- ODTXSELLOdyssey Therapeutics, Inc.$870MQ 19$18.12-5.59%
- ALMSSELLAlumis Inc.$860MCRISISQ 0$6.97-7.08%
- ATTOSELLAttovia Therapeutics, Inc.$702MQ -46$16.31+0.89%
- ACRSSELLAclaris Therapeutics, Inc.$529MCRISISQ 9$3.79-3.61%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 20
- VALUE
- 8
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-12.5%
REV YoY-
ROE-20.8%
EPS YoY-
ROA-11.7%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-31.66
P/E FWD-
SECTOR PE-
INDUSTRY PE13.84
P/B4.41
P/FCF-
EV/EBITDA-31.41
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.23
ALTMAN Z-
CURR RATIO38.51
ND/EBITDA-
BETA-0.39
Company news
FAQ
- What is LOPJLB’s current signal on ORKA?
- LOPJLB’s latest quantitative signal on Oruka Therapeutics, Inc. (ORKA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ORKA in?
- Oruka Therapeutics, Inc. (ORKA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Oruka Therapeutics, Inc. (ORKA) do?
- Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleuki…